Kenneth J Caldwell, Esther De La Cuesta, Cara Morin, Alberto Pappo, Sara Helmig
Pediatric blood & cancer 2020 SepInfantile fibrosarcoma (IFS) is a rare pediatric cancer that typically presents early in life. Surgical resection is commonly curative; however, resection is sometimes not possible requiring additional multimodal treatment. IFS commonly harbors a fusion in one of the neurotrophic receptor tyrosine kinase (NTRK) genes. Larotrectinib, a highly selective inhibitor of tropomyosin receptor kinase (TRK), has been shown to be well tolerated and effective in children as young as 1-month old. We report a case of IFS in a newborn treated with larotrectinib. The patient experienced a rapid clinical and radiographic response demonstrating the potential to treat newborns with larotrectinib. © 2020 Wiley Periodicals, Inc.
Kenneth J Caldwell, Esther De La Cuesta, Cara Morin, Alberto Pappo, Sara Helmig. A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib. Pediatric blood & cancer. 2020 Sep;67(9):e28330
PMID: 32452122
View Full Text